{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:28:50Z","timestamp":1773923330868,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ctrv.2016.09.008","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T19:21:57Z","timestamp":1473708117000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature"],"prefix":"10.1016","volume":"55","author":[{"given":"Gwena\u00eblle","family":"Gravis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Linassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Rebillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Richaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thiery Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Vincendeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.09.008_b0005","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ejca.2013.09.002","article-title":"Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory","volume":"51","author":"Arnold","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.008_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2016.09.008_b0015","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.28485","article-title":"No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","volume":"120","author":"Wu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.008_b0030","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0035","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","article-title":"Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning","volume":"169","author":"Glass","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0050","article-title":"Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","author":"Gravis","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0060","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.09.008_b0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0070","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.eururo.2014.09.022","article-title":"Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model","volume":"68","author":"Gravis","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0080","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0090-4295(02)01741-7","article-title":"Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review","volume":"60","author":"Fakih","year":"2002","journal-title":"Urology"},{"issue":"494","key":"10.1016\/j.ctrv.2016.09.008_b0090","first-page":"e15","article-title":"Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?","volume":"33","author":"Kongsted","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0095","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","article-title":"Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer","volume":"28","author":"Franke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0100","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ejca.2013.11.034","article-title":"Patients\u201c self-assessment versus investigators\u201d evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)","volume":"50","author":"Gravis","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.008_b0105","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0115","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.eururo.2008.07.078","article-title":"Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer","volume":"55","author":"Italiano","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0120","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0125","doi-asserted-by":"crossref","first-page":"S493","DOI":"10.1016\/S0959-8049(16)31371-5","article-title":"Real life treatment sequences and survival of men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabazitaxel in UK clinical practice","volume":"51","author":"Pan","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.09.008_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.01.029","article-title":"New clinical indications for (18)F\/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature","author":"Evangelista","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.09.008_b0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00259-015-3177-4","article-title":"(11)C-choline PET\/CT in castration-resistant prostate cancer patients treated with docetaxel","volume":"43","author":"Ceci","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2016.09.008_b0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2016.09.008_b0145","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0150","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.09.008_b0155","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.09.008_b0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T10:26:47Z","timestamp":1536402407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":32,"alternative-id":["S0305737216300883"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}